Evaluation of the Antitumor Activity of Dacomitinib in Models of Human Bladder Cancer
Abstract Members of the human epidermal growth factor receptor (HER) family play a significant role in bladder cancer progression and may underlie the development of chemotherapy resistance. Dacomitinib is an irreversible tyrosine kinase inhibitor with structural specificity for the catalytic domain...
Päätekijät: | Petros D. Grivas, Kathleen C. Day, Andreas Karatsinides, Alyssa Paul, Nazia Shakir, Iya Owainati, Monica Liebert, Lakshmi P. Kunju, Dafydd Thomas, Maha Hussain, Mark L. Day |
---|---|
Aineistotyyppi: | Artikkeli |
Kieli: | English |
Julkaistu: |
BMC
2013-10-01
|
Sarja: | Molecular Medicine |
Aiheet: | |
Linkit: | https://doi.org/10.2119/molmed.2013.00108 |
Samankaltaisia teoksia
-
Efficacy of dacomitinib in patients with EGFR‐mutated NSCLC and brain metastases
Tekijä: Jinyao Zhang, et al.
Julkaistu: (2021-12-01) -
Virtual screening of Osimertinib and Dacomitinib Analogues with potential activity on EGFR (T790M and l858R Mutations) for non-small cell lung cancer treatment
Tekijä: Leydis Luna Torres, et al.
Julkaistu: (2021-10-01) -
The difference between dacomitinib and afatinib in effectiveness and safety in first-line treatment of patients with advanced EGFR-mutant non-small cell lung cancer: a real-world observational study
Tekijä: Wen-Chien Cheng, et al.
Julkaistu: (2024-02-01) -
Effects of H2-Receptor Antagonists on the Exposure of Dacomitinib
Tekijä: Jian Liu, et al.
Julkaistu: (2024-01-01) -
Real-world data of dacomitinib as first-line treatment for patients with EGFR-mutant non-small-cell lung cancer
Tekijä: Ji Eun Shin, et al.
Julkaistu: (2025-02-01)